Logo image of CALC

CALCIMEDICA INC (CALC) Stock Price, Quote, News and Overview

NASDAQ:CALC - Nasdaq - US38942Q2021 - Common Stock - Currency: USD

2.35  -0.09 (-3.69%)

CALC Quote, Performance and Key Statistics

CALCIMEDICA INC

NASDAQ:CALC (2/21/2025, 8:05:04 PM)

2.35

-0.09 (-3.69%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High6.27
52 Week Low2.05
Market Cap31.68M
Shares13.48M
Float10.56M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-26 2025-03-26/amc
IPO09-25 2020-09-25


CALC short term performance overview.The bars show the price performance of CALC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

CALC long term performance overview.The bars show the price performance of CALC in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of CALC is 2.35 USD. In the past month the price decreased by -18.69%. In the past year, price decreased by -47.66%.

CALCIMEDICA INC / CALC Daily stock chart

CALC Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 67.21 829.40B
NVO NOVO-NORDISK A/S-SPONS ADR 27.53 390.99B
JNJ JOHNSON & JOHNSON 16.25 390.76B
AZN ASTRAZENECA PLC-SPONS ADR 20.56 230.17B
MRK MERCK & CO. INC. 11.71 226.40B
NVS NOVARTIS AG-SPONSORED ADR 13.77 215.98B
PFE PFIZER INC 8.46 149.04B
SNY SANOFI-ADR 13.62 136.54B
BMY BRISTOL-MYERS SQUIBB CO 48.97 113.23B
GSK GSK PLC-SPON ADR 7.81 74.77B
ZTS ZOETIS INC 27.1 72.39B
TAK TAKEDA PHARMACEUTIC-SP ADR 31.95 44.58B

About CALC

Company Profile

CALC logo image CalciMedica, Inc. operates as a biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 14 full-time employees. The company went IPO on 2020-09-25. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

Company Info

CALCIMEDICA INC

505 Coast Boulevard South, Suite 307

La Jolla CALIFORNIA US

Employees: 13

Company Website: https://calcimedica.com/

Investor Relations: https://ir.calcimedica.com/

Phone: 18589525500

CALCIMEDICA INC / CALC FAQ

What is the stock price of CALCIMEDICA INC today?

The current stock price of CALC is 2.35 USD. The price decreased by -3.69% in the last trading session.


What is the ticker symbol for CALCIMEDICA INC stock?

The exchange symbol of CALCIMEDICA INC is CALC and it is listed on the Nasdaq exchange.


On which exchange is CALC stock listed?

CALC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CALCIMEDICA INC stock?

10 analysts have analysed CALC and the average price target is 16.32 USD. This implies a price increase of 594.47% is expected in the next year compared to the current price of 2.35. Check the CALCIMEDICA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CALCIMEDICA INC worth?

CALCIMEDICA INC (CALC) has a market capitalization of 31.68M USD. This makes CALC a Nano Cap stock.


How many employees does CALCIMEDICA INC have?

CALCIMEDICA INC (CALC) currently has 13 employees.


What are the support and resistance levels for CALCIMEDICA INC (CALC) stock?

CALCIMEDICA INC (CALC) has a resistance level at 2.52. Check the full technical report for a detailed analysis of CALC support and resistance levels.


Should I buy CALCIMEDICA INC (CALC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CALCIMEDICA INC (CALC) stock pay dividends?

CALC does not pay a dividend.


When does CALCIMEDICA INC (CALC) report earnings?

CALCIMEDICA INC (CALC) will report earnings on 2025-03-26, after the market close.


What is the Price/Earnings (PE) ratio of CALCIMEDICA INC (CALC)?

CALCIMEDICA INC (CALC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.08).


What is the Short Interest ratio of CALCIMEDICA INC (CALC) stock?

The outstanding short interest for CALCIMEDICA INC (CALC) is 0.65% of its float. Check the ownership tab for more information on the CALC short interest.


CALC Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CALC Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CALC. The financial health of CALC is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CALC Financial Highlights

Over the last trailing twelve months CALC reported a non-GAAP Earnings per Share(EPS) of -1.08. The EPS increased by 94.81% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -83.81%
ROE -150.48%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%39.02%
Sales Q2Q%N/A
EPS 1Y (TTM)94.81%
Revenue 1Y (TTM)N/A

CALC Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to CALC. The Buy consensus is the average rating of analysts ratings from 10 analysts.


Ownership
Inst Owners52.43%
Ins Owners11.99%
Short Float %0.65%
Short Ratio1.48
Analysts
Analysts84
Price Target16.32 (594.47%)
EPS Next Y95.08%
Revenue Next YearN/A